News | March 09, 2023
Evonik opens new facility for pharmaceutical lipids in Germany
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Clinical studies are expected to start in Q2 2023.
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
